Aerovate Therapeutics, Inc. |
Director |
Common Stock |
1.78M |
$50.2M |
$28.15 |
Apr 9, 2024 |
By Atlas Venture Fund XII, L.P. |
Homology Medicines, Inc. |
Director |
Common Stock |
864K |
$494K |
$0.57 |
Mar 25, 2024 |
By Atlas Venture Fund X, L.P. |
Homology Medicines, Inc. |
Director |
Common Stock |
725K |
$414K |
$0.57 |
Mar 25, 2024 |
By Atlas Venture Opportunity Fund II, L.P. |
Aerovate Therapeutics, Inc. |
Director |
Common Stock |
14.5K |
$408K |
$28.15 |
Apr 9, 2024 |
By Atlas Venture Associates XII, L.P. |
Homology Medicines, Inc. |
Director |
Common Stock |
503K |
$287K |
$0.57 |
Mar 25, 2024 |
By Atlas Venture Opportunity Fund I, L.P. |
Aerovate Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
12.5K |
$205K |
$16.37 |
Jun 5, 2024 |
Direct |
Q32 Bio Inc. |
Director |
Stock Option (Right to Buy) |
2.57K |
$34.5K |
$13.42 |
Apr 1, 2024 |
Direct |
Surface Oncology, Inc. |
Director |
Common Stock |
0 |
|
$0.94 |
Sep 8, 2023 |
Indirect |